Mark’s research activities encompass clinical, translational and basic science programmes on the biology of renal cancer, with specific interests in the molecular mechanisms of disease progression, disease response and novel minimally invasive treatments of small renal cancers (SRM’s). He also has research interests in mechanisms of erectile dysfunction. He has been on the NCRI Renal Cancer Studies group for 7 years and has been involved in a number of national clinical trials involving surgical and chemotherapy treatments for renal cancer.